Abstract
Theravance is developing telavancin, an injectable peptidoglycan inhibitor antibiotic for potential use in the treatment of Gram-positive bacterial infection. Phase III trials in complicated skin and skin structure infections commenced in September 2004.
MeSH terms
-
Aminoglycosides / adverse effects
-
Aminoglycosides / chemical synthesis
-
Aminoglycosides / metabolism
-
Aminoglycosides / pharmacokinetics
-
Aminoglycosides / pharmacology*
-
Aminoglycosides / therapeutic use
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Contraindications
-
Drug Evaluation, Preclinical
-
Gram-Positive Bacterial Infections / drug therapy*
-
Gram-Positive Bacterial Infections / microbiology
-
Lipoglycopeptides
-
Structure-Activity Relationship
Substances
-
Aminoglycosides
-
Lipoglycopeptides
-
telavancin